{"nctId":"NCT02219490","briefTitle":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","startDateStruct":{"date":"2014-10-30","type":"ACTUAL"},"conditions":["Chronic Hepatitis C Virus (HCV) Infection Genotype 1"],"count":1596,"armGroups":[{"label":"ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: Ribavirin (RBV)"]}],"interventions":[{"name":"ABT-450/r/ABT-267","otherNames":["ABT-450 also known as paritaprevir","ABT-267 also known as ombitasvir","Paritaprevir/ritonavir/ombitasvir also known as Viekirax"]},{"name":"ABT-333","otherNames":["ABT-333 also known as dasabuvir","ABT-333 also known as Exviera"]},{"name":"Ribavirin (RBV)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and females at least 18 years old at screening\n2. Females must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control\n3. Chronic hepatitis C, genotype 1 infection\n4. Males must be surgically sterile or agree to practice acceptable forms of birth control\n5. Screening laboratory result indicating HCV genotype 1 infection\n\nExclusion Criteria:\n\n1. Use of contraindicated medications within 2 weeks of dosing\n2. Abnormal laboratory tests\n3. Current or past clinical evidence of Child-Pugh B or C classification or history of liver decompensation\n4. Confirmed presence of hepatocellular carcinoma\n5. History of solid organ transplant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"All-Cause Death: Time to Event","description":"Time to all-cause death was defined as the number of days from the first day of study drug dosing for the participant to the date of death. All deaths were to be included, regardless of whether the death occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant did not die, their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, the participant's data was to be censored on the first day of study drug dosing. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of all-cause death included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Liver-Related Death: Time to Event","description":"Time to liver-related death was defined as days from the 1st day of study drug dosing for the subject to date of liver-related death. All liver-related deaths were to be included, regardless of whether the death occurred while subject was still taking study drug or had previously discontinued study drug. If the subject didn't experience event of interest nor had died (all-cause death), their data was to be censored at date of last available assessment. For those with no post-baseline assessment, data was to be censored on 1st day of study drug dosing. All-cause death was a censoring event for liver-related death. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of liver-related death included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Liver Decompensation: Time to Event","description":"Time to liver decompensation was defined as number of days from the 1st day of study drug dosing for the participant to the date of liver decompensation. All liver decompensation was to be included, regardless of whether it occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant didn't experience the event of interest nor had died (all-cause death), their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, their data was to be censored on the 1st day of study drug dosing. All-cause death was a censoring event for liver decompensation. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of liver decompensation included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Liver Transplantation: Time to Event","description":"Time to liver transplantation was defined as days from 1st day of study drug dosing for subject to date of liver transplantation. All liver transplantation was to be included, whether it occurred while the subject was still taking study drug or had previously discontinued study drug. If the subject didn't experience event of interest nor had died (all-cause death), their data was to be censored at the date of their last available assessment. For those with no post-baseline assessment, data was to be censored on 1st day of study drug dosing. All-cause death was a censoring event for liver transplantation. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of liver transplantation included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Hepatocellular Carcinoma: Time to Event","description":"Time to hepatocellular carcinoma (HCC) was defined as number of days from 1st day of study drug dosing for subject to date of hepatocellular carcinoma. All HCC was to be included, whether it occurred while subject was still taking study drug or had previously discontinued study drug. If the subject didn't experience the event of interest nor had died (all-cause death), their data was to be censored at the date of their last available assessment. For those with no post-baseline assessment, their data was to be censored on the 1st day of study drug dosing. All-cause death was a censoring event for HCC. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of hepatocellular carcinoma included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"PRIMARY","title":"All-Cause Death, Liver-Related Death, Liver Decompensation, Liver Transplantation, Hepatocellular Carcinoma: Time to Event","description":"Time to the composite of clinical outcomes is the time to the first occurrence of all-cause death, liver-related death, liver decompensation, liver transplantation, or hepatocellular carcinoma. All first occurrences were to be included, regardless of whether it occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant did not experience any of these events, their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, the participant's data was to be censored on the first day of study drug dosing. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. Pre-specified analysis included pooled data from this study and from TOPAZ-II; NCT02167945.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FibroScan Score by SVR12 Status","description":"The FibroScan test is a validated non-invasive test used to assess liver fibrosis in participants with chronic liver disease, and it was performed at study sites where it was available. For participants with Hepatitis C infection, a FibroScan score of 2-7 kPa indicates no liver scarring or mild scarring; a score of 8 or 9 is associated with moderate liver scarring; 9-14 indicates severe liver scarring; and 14 or higher is indicative of advanced liver scarring, cirrhosis. Negative changes from baseline indicate improvement in liver fibrosis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.55","spread":"3.282"},{"groupId":"OG001","value":"-1.41","spread":"4.283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"2.624"},{"groupId":"OG001","value":"-1.76","spread":"4.213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"3.211"},{"groupId":"OG001","value":"-1.98","spread":"4.363"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"1.986"},{"groupId":"OG001","value":"-2.46","spread":"4.858"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"3.306"},{"groupId":"OG001","value":"-2.80","spread":"5.195"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"3.999"},{"groupId":"OG001","value":"-2.92","spread":"5.249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"2.445"},{"groupId":"OG001","value":"-3.08","spread":"5.560"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"3.706"},{"groupId":"OG001","value":"-3.08","spread":"5.662"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug. Flanking imputation, where applicable, was used to impute missing data. After applying flanking imputation, if there was no value in the window but there was an HCV RNA value from a local laboratory present, then it was to be imputed into the SVR window. Otherwise, participants with missing data were counted as failures.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":1596},"commonTop":["FATIGUE","HEADACHE","PRURITUS","NAUSEA","INSOMNIA"]}}}